GH
PACB icon

Grosvenor Holdings’s Pacific Biosciences PACB Stock Holding History

Grosvenor Holdings’s Portfolio PACB Stock Details PACB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		$355K Buy
+39,037
New +$449K 0.07% 14

Other funds holding PACB

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
JSP
Jackson Square Partners Larkspur, California $247M AUM 20.29% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Grosvenor Holdings's PACB Position: Q1 2022 in Review

Grosvenor Holdings opened a new position in Pacific Biosciences (PACB) in Q1 2022: 39,037 shares worth $355K. The stake represents 0.07% of the portfolio and ranks #14 among its holdings.

250 funds tracked by Wall St. Rank hold PACB as of Q1 2022.

  • Grosvenor Holdings held 39,037 shares of Pacific Biosciences worth $355K as of Q1 2022.
  • Pacific Biosciences was a new Grosvenor Holdings position in Q1 2022.
  • Pacific Biosciences made up 0.07% of Grosvenor Holdings's portfolio in Q1 2022, its #14 holding.
  • 250 funds tracked by Wall St. Rank held Pacific Biosciences as of Q1 2022.

Based on Grosvenor Holdings's 13F filing for Q1 2022, filed 16 May 2022.